Pharmaceuticals

Imbria's ninerafaxstat gains FDA Orphan Drug status for nHCM, a rare heart condition. This strategic win pits its unique metabolic approach against rivals.

Heparin, a trusted blood thinner, can trigger a fatal immune reaction. A small biotech's novel drug is now taking the global stage with a targeted solution.

A novel drug for glioblastoma enters a revolutionary trial, but the real story is the mission-driven company behind it, rewriting the rules of drug development.

Novartis is betting nearly $2 billion on Antares Therapeutics' novel platform to conquer historically 'undruggable' cancer targets, a move that could redefine oncology.

Ollin Biosciences secured $330M to challenge giants like Roche and Regeneron. Their next-gen antibody shows early promise in treating vision loss.

An alliance of biopharma innovators is set to discuss a critical hurdle in medicine: delivering RNA therapies to tissues beyond the liver, a key to unlocking new treatments.

BOTOX® Cosmetic is investing millions in women entrepreneurs. Is it smart philanthropy, or a brilliant new blueprint for brand building and corporate strategy?

A new $5M partnership promises better patient support. We analyze the model, the money, and the ethical tightrope of pharma-nonprofit collaborations.

As Julie Kim becomes Takeda's new CEO, she inherits a robust pipeline and a fortified board, signaling a strategic shift toward executional excellence.

A massive $115M funding round fuels UK biotech RQ Bio's quest to replace the annual flu shot for the vulnerable with a single, season-long antibody treatment.

A novel drug designed by AI to prevent a crippling side effect of chemotherapy has received dual US and Taiwan regulatory approval, paving the way for human trials.

Beyond oil, Abu Dhabi is building a global life sciences hub. A new partnership with Sanofi to create a Vaccine Innovation Centre is its boldest move yet.

Telehealth platforms like TWL promise easier access to weight-loss drugs, but a closer look reveals a complex world of insurance battles and risky compounds.

Telehealth firms now offer needle-free weight-loss pills. As companies like FitRx expand access, they enter a regulatory minefield of unapproved drugs.

Early trial data for Verastem Oncology's VS-7375 reveals significant anti-tumor activity and a good safety profile, igniting hope for tough-to-treat cancers.

New telehealth platforms promise to unlock Zepbound by navigating insurance mazes. But are they building a safe superhighway or a risky digital backroad?

A new €35,000 grant fuels Canadian gut health research, highlighting a strategic play where corporate philanthropy meets a multi-billion dollar market.

A new report shows AI directs 80% of aesthetic medicine searches to AbbVie & Galderma, creating a 'visibility gap' that leaves 11,500 small clinics invisible.

A new book on psilocybin therapy for women signals a strategic shift from clinical data to lived experience, building a new market in the wellness economy.

A landmark partnership between Merck and Mae aims to professionalize the doula workforce, using tech to fight deep-seated maternal health disparities.